.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts
Johnson and Johnson
Julphar
Teva
Fish and Richardson
US Department of Justice
Chinese Patent Office
Queensland Health
Daiichi Sankyo

Generated: November 24, 2017

DrugPatentWatch Database Preview

AMYVID Drug Profile

« Back to Dashboard

What is the patent landscape for Amyvid, and when can generic versions of Amyvid launch?

Amyvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There are two patents protecting this drug.

This drug has forty-one patent family members in thirty-one countries and thirteen supplementary protection certificates in thirteen countries.

The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this compound. Additional details are available on the florbetapir f-18 profile page.

Summary for AMYVID

Pharmacology for AMYVID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-001Apr 6, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-003Apr 6, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-002Apr 6, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-003Apr 6, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-001Apr 6, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-001Apr 6, 2012DISCNNoNo► Subscribe► Subscribe► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-002Apr 6, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-002Apr 6, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Avid Radiopharms Inc
AMYVID
florbetapir f-18
SOLUTION;INTRAVENOUS202008-003Apr 6, 2012RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: AMYVID

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,840,866Styrylpyridine derivatives and their use for binding and imaging amyloid plaques► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: AMYVID

Country Document Number Estimated Expiration
Lithuania2363392► Subscribe
New Zealand570887► Subscribe
BrazilPI0710225► Subscribe
Slovenia1999109► Subscribe
EcuadorSP088783► Subscribe
Canada2644530► Subscribe
European Patent Office2363391► Subscribe
European Patent Office2363392► Subscribe
China101522624► Subscribe
Spain2378785► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: AMYVID

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
9 5017-2013Slovakia► SubscribePRODUCT NAME: FLORBETAPIR ( 18 F); REGISTRATION NO/DATE: EU/1/12/805 20130114
/2013Austria► SubscribePRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: EU/1/12/805 20130114
1999109/01Switzerland► SubscribePRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: SWISSMEDIC 62897 09.01.2014
1Finland► Subscribe
2013016Lithuania► SubscribePRODUCT NAME: FLORBETAPIRUM; REGISTRATION NO/DATE: EU/1/12/805 20130114
0130016 00076Estonia► SubscribePRODUCT NAME: FLORBETAPIIR (18F);REG NO/DATE: K(2013)137 (LOPLIK) 14.01.2013
2013000051Germany► SubscribePRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: EU/1/12/805 20130114
13/028Ireland► SubscribePRODUCT NAME: FLORBETAPIR (18F), OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/12/805 20130114
C0034France► SubscribePRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: EU/1/12/805 20130114
2013 00035Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Daiichi Sankyo
Cantor Fitzgerald
Teva
AstraZeneca
US Department of Justice
Citi
Medtronic
Queensland Health
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot